These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2917113)

  • 41. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
    Ording H; Bendixen D
    Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Screening tests for malignant hyperthermia susceptibility].
    Krivosic-Horber R; Adnet P
    Ann Fr Anesth Reanim; 1989; 8(5):444-56. PubMed ID: 2560612
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determining the utility of the 60 min cortisol measurement in the short synacthen test.
    Chitale A; Musonda P; McGregor AM; Dhatariya KK
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):14-9. PubMed ID: 22747889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
    Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
    Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment?
    Le Roux CW; Meeran K; Alaghband-Zadeh J
    Ann Clin Biochem; 2002 Mar; 39(Pt 2):148-50. PubMed ID: 11930947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diltiazem and nifedipine reduce the in vitro contracture response to halothane in malignant hyperthermia-susceptible muscle.
    Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Reyford HG; Adamantidis MM; Dupuis BA
    Can J Anaesth; 1990 Jul; 37(5):556-9. PubMed ID: 2372858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physiological cortisol substitution of long-term steroid-treated patients undergoing major surgery.
    Symreng T; Karlberg BE; Kågedal B; Schildt B
    Br J Anaesth; 1981 Sep; 53(9):949-54. PubMed ID: 6793052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Muscle biopsy for malignant hyperthermia screening in children.
    Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
    Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The work of the Leeds Malignant Hyperpyrexia Unit, 1971-84.
    Ellis FR; Halsall PJ; Harriman DG
    Anaesthesia; 1986 Aug; 41(8):809-15. PubMed ID: 3752463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. How good is a morning cortisol in predicting an adequate response to intramuscular synacthen stimulation?
    Yo WS; Toh LM; Brown SJ; Howe WD; Henley DE; Lim EM
    Clin Endocrinol (Oxf); 2014 Jul; 81(1):19-24. PubMed ID: 24274236
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anthropometric studies of human subjects susceptible to malignant hyperpyrexia.
    Campbell IT; Ellis FR; Halsall PJ; Hogge MS
    Acta Anaesthesiol Scand; 1982 Aug; 26(4):363-7. PubMed ID: 7124314
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of sampling times and serum cortisol cut-off concentrations on the routine assessment of adrenal function using the standard cosyntropin test in an academic hospital from Spain: a retrospective chart review.
    Ortiz-Flores AE; Santacruz E; Jiménez-Mendiguchia L; García-Cano A; Nattero-Chávez L; Escobar-Morreale HF; Luque-Ramírez M
    BMJ Open; 2018 May; 8(5):e019273. PubMed ID: 29730618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
    Glauber V; Ben Abraham R; Zweig A; Perel A
    Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis and management of susceptibility to malignant hyperthermia in pregnancy.
    Sorosky JI; Ingardia CJ; Botti JJ
    Am J Perinatol; 1989 Jan; 6(1):46-8. PubMed ID: 2910318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Telephone enquiries on the topic of malignant hyperthermia: Evaluation of the content and subsequent diagnostic results at the MH Center Leipzig].
    Petersen B; Busch T; Meinecke CD; Börge B; Kluba K; Kaisers UX; Rüffert H
    Anaesthesist; 2016 Jan; 65(1):36-41. PubMed ID: 26481388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Muscle biopsy proven malignant hyperpyrexia and minimal symptoms under inhalational anaesthesia.
    Pemberton DM
    Anaesth Intensive Care; 1991 Feb; 19(1):133-4. PubMed ID: 2012285
    [No Abstract]   [Full Text] [Related]  

  • 58. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
    Britt BA; Scott EA
    Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrastructure of human muscle in malignant hyperthermia.
    Reske-Nielsen E
    Acta Pathol Microbiol Scand A; 1973 Jul; 81(4):585-7. PubMed ID: 4779709
    [No Abstract]   [Full Text] [Related]  

  • 60. Sudden death due to malignant hyperthermia.
    Pamukcoglu T
    Am J Forensic Med Pathol; 1988 Jun; 9(2):161-2. PubMed ID: 3381797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.